TP53 and B-cell chronic lymphocytic leukemia: The majority of patients with relapsed or refractory CLL carry poor prognostic features, like, deletion (17p) or TP53 mutation, which are strong predictors of shorter overall survival and resistance to first-line treatment, particularly fludarabine-based regimens [1, 2].